Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center
Advertisement
Articles by Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center
Advertisement
Latest Updated Articles
Management of Adverse Effects in R/R HER2+ mBCSeptember 23rd 2020
FDA-approved Therapies for Relapsed/Refractory HER2+ mBCSeptember 23rd 2020
Practical Management of Early Stage HER2+ Breast CancerSeptember 23rd 2020
HER2-targeted Therapy: Routes of AdministrationSeptember 23rd 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma
3
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis
4
CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL
5